Interactive Career Planning and Development

• Laurie Parker, University of Minnesota, Minneapolis, MN

Biomarkers for Early Detection

• Birgit Schilling, The Buck Institute, Novato, CA
• Karin Rodland, PNNL, Richland, WA

How to Bring the Impact of Multi-omics Research to the Next Level? From Industry and Academic Perspectives

• Yu Tian, AbbVie, Worcester, MA
• Justin Wade Davis, AbbVie, Chicago, IL
• Thomas Conrads, WHIRC at Inova, Fairfax, VA
• Christopher Mason, Weill Cornell Medicine, New York, NY

Cardiovascular Proteomics in Translational and Clinical Research: How to Accelerate "Bench-to-Bedside" Translation?

• Sarah Parker, Cedars Sinai, Los Angeles, CA
• Lisandra de Castro Bras, East Carolina University, Greenville, NC
• Edward Lau, CU Anschutz Medical Campus, Aurora, CO
• Johnathan Kirk, Loyola University Chicago, Chicago, IL

Putting Humpty Dumpty Back Together Again: What Does Protein Quant Mean in Bottom-Up Proteomics?

• Michael MacCoss, University of Washington, Seattle, WA
• Brian Searle, Institute for Systems Biology, Seattle, WA

Top-down Proteomics: Tips and Tricks for Beginners

• Si Wu, University of Oklahoma, Norman, OK
• Nick Young, Baylor College of Medicine, Houston, TX

TaMADOR - Targeted Mass Spectrometric Assays for Diabetes and Obesity Research

• Salvatore Sechi, NIDDK/NIH
• Jenny Van Eyk, Cedars-Sinai
• Cory Bystrom, Cedars-Sinai
• Wei-Jun Qian, PNNL
• Andy Hoofnagle, University of Washington
• Michael MacCoss, University of Washington
• Jun Qu, SUNY-Buffalo

The NIDDK recently started a program for developing mass spectrometric assays for proteins and peptides of primary interest to the obesity and diabetes research community. These assays should be highly reproducible, easily transferable to other laboratories, and validated in human plasma or serum. Examples, of proteins and peptides that are of potential interest include insulin, glucagon, c-peptide, glycated CD59, Adiponectin, Leptin, Resistin, Neuropeptide Y, Alpha-melanocyte-stimulating hormone, Peptide YY, Glucagon-like peptide 1, Ghrelin, Adrenocorticotropin, Corticotropin-releasing hormone, Gastrin, , Vasoactive intestinal peptide, gastric-inhibitory peptide, gastrin-releasing peptide, motilin, pancreatic polypeptide, myostatin, and  FGF21). We will introduce the TaMADOR (Targeted Mass Spectrometric Assays for Diabetes and Obesity Research) program and discuss how we might proceed in developing, validating, and implementing MS assays of interest to the Obesity and Diabetes community.